Loading
companiesCompany
Betta Pharmaceuticals
Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval.
Also called: 贝达药业
Overview
Betta Pharmaceuticals, based in Hangzhou, founded in 2003 and listed as 300558.SZ, made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval. Icotinib, sold as Conmana, was approved in 2011; ensartinib, sold as Ensacove, was approved in China in 2020 and by the FDA in December 2024 for ALK-positive non-small-cell lung cancer through Xcovery; befotertinib from InventisBio was approved in 2023; and the company holds China rights to the MCLA-129 EGFR by c-MET bispecific from Merus. OnCo links it to icotinib and ensartinib and to InventisBio and Merus. Whether an FDA approval for ensartinib translates into US sales against entrenched ALK drugs is the open question. Ensartinib has its own page.
Headquarters
Hangzhou, CN
Scorecard
All companies#80of 1244 companies, score 57
- approved products +18
- phase 1/2 +2
- targets +8
- modalities +4
- regions +2
- registry trials +23
3 approved, 0 in phase 3, 2 earlier, 4 targets, 129 registry studies. Formula on the scorecards page.
Type
Biotech · 300558.SZ
Stage
Public
Website
Founded
2003
ApprovedSmall-molecule first-generation EGFR TKI
Icotinib · Conmana
Icotinib, approved in 2011, was the first cancer drug invented and developed in China, and it showed that a domestic lung cancer pill could match a Western one head to head.
ApprovedSmall-molecule ALK TKI (second generation)
Ensartinib · Ensacove
A Chinese-developed ALK pill approved in the US in December 2024 for first-line ALK-positive lung cancer.
Phase 2bispecific antibody
MCLA-129 is an experimental bispecific antibody from Betta Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and colorectal cancer, aimed at EGFR and MET.
ApprovedOral kinase inhibitor
Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.
ApprovedOral multi-target VEGFR and PDGFR tyrosine kinase inhibitor
Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed.
Similar pages
- TreatmentGarsorasib
Shares InventisBio and the tag china.
- TrialUmbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
Shares Icotinib, Ensartinib.
fronts
drugs
ApprovedOral kinase inhibitor
ApprovedSmall-molecule ALK TKI (second generation)
Ensartinib · Ensacove
ApprovedSmall-molecule first-generation EGFR TKI
Icotinib · Conmana
Phase 2bispecific antibody
ApprovedOral multi-target VEGFR and PDGFR tyrosine kinase inhibitor
companies
trials
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerAdjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsAdjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDSequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIStudy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASStudy of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors